Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-299-8380
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$90.27 million
Profitability
Miscellaneous
Employees637
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
SAGE Therapeutics (NASDAQ:SAGE) Frequently Asked Questions
What is SAGE Therapeutics' stock symbol?
SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."
How were SAGE Therapeutics' earnings last quarter?
SAGE Therapeutics Inc (NASDAQ:SAGE) released its quarterly earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($3.28) EPS for the quarter, beating analysts' consensus estimates of ($3.32) by $0.04. The biopharmaceutical company earned $0.87 million during the quarter, compared to analysts' expectations of $0.27 million. The company's quarterly revenue was down 99.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.36) earnings per share. View SAGE Therapeutics' Earnings History.
When is SAGE Therapeutics' next earnings date?
What price target have analysts set for SAGE?
14 Wall Street analysts have issued 12 month price objectives for SAGE Therapeutics' stock. Their predictions range from $80.00 to $261.00. On average, they expect SAGE Therapeutics' share price to reach $200.2727 in the next twelve months. This suggests a possible upside of 24.8% from the stock's current price. View Analyst Price Targets for SAGE Therapeutics.
What is the consensus analysts' recommendation for SAGE Therapeutics?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SAGE Therapeutics.
Has SAGE Therapeutics been receiving favorable news coverage?
News articles about SAGE stock have trended negative on Wednesday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. SAGE Therapeutics earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for SAGE Therapeutics.
Who are some of SAGE Therapeutics' key competitors?
Some companies that are related to SAGE Therapeutics include Shiseido (SSDOY), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TAK), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Mylan (MYL), Array Biopharma (ARRY), Elanco Animal Health (ELAN) and Alnylam Pharmaceuticals (ALNY).
What other stocks do shareholders of SAGE Therapeutics own?
Who are SAGE Therapeutics' key executives?
SAGE Therapeutics' management team includes the folowing people:
- Dr. Jeffrey M. Jonas, CEO, Pres & Director (Age 66)
- Ms. Kimi E. Iguchi, CFO & Treasurer (Age 57)
- Dr. Albert J. Robichaud, Chief Scientific Officer (Age 58)
- Ms. Anne Marie Cook, Sr. VP, Gen. Counsel & Sec. (Age 57)
- Mr. Michael Cloonan, Chief Bus. Officer (Age 48)
Who are SAGE Therapeutics' major shareholders?
SAGE Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (15.30%), Vanguard Group Inc. (8.92%), Jennison Associates LLC (5.72%), BlackRock Inc. (5.32%), BlackRock Inc. (5.32%) and Invesco Ltd. (3.91%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Institutional Ownership Trends for SAGE Therapeutics.
Which institutional investors are selling SAGE Therapeutics stock?
SAGE stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Price T Rowe Associates Inc. MD, Bank of New York Mellon Corp, Farallon Capital Management LLC, Strs Ohio, Senator Investment Group LP, Candriam Luxembourg S.C.A. and Bank of America Corp DE. Company insiders that have sold SAGE Therapeutics company stock in the last year include Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Insider Buying and Selling for SAGE Therapeutics.
Which institutional investors are buying SAGE Therapeutics stock?
SAGE stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., Nuveen Asset Management LLC, Jennison Associates LLC, Janus Henderson Group PLC, Janus Henderson Group PLC, BlackRock Inc., BlackRock Inc. and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for SAGE Therapeutics.
How do I buy shares of SAGE Therapeutics?
Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is SAGE Therapeutics' stock price today?
One share of SAGE stock can currently be purchased for approximately $160.48.
How big of a company is SAGE Therapeutics?
SAGE Therapeutics has a market capitalization of $8.21 billion and generates $90.27 million in revenue each year. The biopharmaceutical company earns $-372,880,000.00 in net income (profit) each year or ($8.08) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.View Additional Information About SAGE Therapeutics.
What is SAGE Therapeutics' official website?
How can I contact SAGE Therapeutics?
SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]
MarketBeat Community Rating for SAGE Therapeutics (NASDAQ SAGE)
MarketBeat's community ratings are surveys of what our community members think about SAGE Therapeutics and other stocks. Vote "Outperform" if you believe SAGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAGE will underperform the S&P 500 over the long term. You may vote once every thirty days.
